Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence

Generalized Pustular Psoriasis Clinical Trial

Official title:

Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04566471
• Other study ID #: BI13680065
• Status: Active, not recruiting
• Start date: January 1, 2012
• Est. completion date: December 31, 2021

Study information

• Verified date: June 2020
• Source: Peking University Third Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study plans to calculate the prevalence and incidence of palmoplantar pustulosis and generalized pustular psoriasis based on the national medical insurance data and analyze the composition characteristics and some clinical features of patients, through taking into account of the research status of palmoplantar pustulosis and generalized pustular psoriasis and the characteristics of medical insurance data.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: December 31, 2021
• Est. primary completion date: December 1, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The insured population of the national urban employee basic medical insurance and the urban resident basic medical insurance from January 1, 2012, to December 31, 2016 (60 months) (the denominator)

• The patients have been diagnosed with palmoplantar pustulosis or generalized pustular psoriasis (including disease name, English abbreviation and ICD code)

• Both outpatient and inpatient patients are included

Exclusion Criteria:

• The individuals whose information is only contained in the reimbursement settlement database but not in the insurance coverage database will be considered as invalid reimbursement individuals and be excluded from the study (the denominator)

• The patients have been diagnosed with non-PPP and -GPP diseases, such as pustular psoriasis in palm and toe, pustular arthritis osteitis and SAPHO syndrome

Related Conditions & MeSH terms

• Generalized Pustular Psoriasis
• Palmoplantar Pustulosis
• Psoriasis

Intervention

Other:
• prevalence/incidence
It is an observational study for prevalence/incidence, no intervention provided.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence of Palmoplantar pustulosis	Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease	From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China
Primary	prevalence of Generalized pustular psoriasis	Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease	From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China
Secondary	incidence of Palmoplantar pustulosis	Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease	From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China
Secondary	incidence of Generalized pustular psoriasis	Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease	From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China
Secondary	Economic burden of Palmoplantar pustulosis	Mainly referring to the consumption of medical resources, including medical expenses of patients.	From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China
Secondary	Economic burden of Generalized pustular psoriasis	Mainly referring to the consumption of medical resources, including medical expenses of patients.	From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China